227 related articles for article (PubMed ID: 34462327)
1. Dual PD-L1 and TGF-b blockade in patients with recurrent respiratory papillomatosis.
Robbins Y; Friedman J; Clavijo PE; Sievers C; Bai K; Donahue RN; Schlom J; Sinkoe A; Hinrichs CS; Allen C; Abdul Sater H; Gulley JL; Norberg S
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34462327
[TBL] [Abstract][Full Text] [Related]
2. Safety and clinical activity of PD-L1 blockade in patients with aggressive recurrent respiratory papillomatosis.
Allen CT; Lee S; Norberg SM; Kovalovsky D; Ye H; Clavijo PE; Hu-Lieskovan S; Schlegel R; Schlom J; Strauss J; Gulley JL; Trepel J; Hinrichs CS
J Immunother Cancer; 2019 May; 7(1):119. PubMed ID: 31053174
[TBL] [Abstract][Full Text] [Related]
3. Tumor in the Crossfire: Inhibiting TGF-β to Enhance Cancer Immunotherapy.
Tschernia NP; Gulley JL
BioDrugs; 2022 Mar; 36(2):153-180. PubMed ID: 35353346
[TBL] [Abstract][Full Text] [Related]
4. Immune suppression in premalignant respiratory papillomas: enriched functional CD4+Foxp3+ regulatory T cells and PD-1/PD-L1/L2 expression.
Hatam LJ; Devoti JA; Rosenthal DW; Lam F; Abramson AL; Steinberg BM; Bonagura VR
Clin Cancer Res; 2012 Apr; 18(7):1925-35. PubMed ID: 22322668
[TBL] [Abstract][Full Text] [Related]
5. Preclinical and clinical studies of bintrafusp alfa, a novel bifunctional anti-PD-L1/TGFβRII agent: Current status.
Gameiro SR; Strauss J; Gulley JL; Schlom J
Exp Biol Med (Maywood); 2022 Jul; 247(13):1124-1134. PubMed ID: 35473390
[TBL] [Abstract][Full Text] [Related]
6. Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients With Non-Small Cell Lung Cancer Resistant or Refractory to Immune Checkpoint Inhibitors.
Barlesi F; Isambert N; Felip E; Cho BC; Lee DH; Peguero J; Jerusalem G; Penel N; Saada-Bouzid E; Garrido P; Helwig C; Locke G; Ojalvo LS; Gulley JL
Oncologist; 2023 Mar; 28(3):258-267. PubMed ID: 36571770
[TBL] [Abstract][Full Text] [Related]
7. The PD-1 and PD-L1 pathway in recurrent respiratory papillomatosis.
Ahn J; Bishop JA; Roden RBS; Allen CT; Best SRA
Laryngoscope; 2018 Jan; 128(1):E27-E32. PubMed ID: 28940446
[TBL] [Abstract][Full Text] [Related]
8. Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort.
Cho BC; Daste A; Ravaud A; Salas S; Isambert N; McClay E; Awada A; Borel C; Ojalvo LS; Helwig C; Rolfe PA; Gulley JL; Penel N
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32641320
[TBL] [Abstract][Full Text] [Related]
9. Enhanced neoepitope-specific immunity following neoadjuvant PD-L1 and TGF-β blockade in HPV-unrelated head and neck cancer.
Redman JM; Friedman J; Robbins Y; Sievers C; Yang X; Lassoued W; Sinkoe A; Papanicolau-Sengos A; Lee CC; Marte JL; Turkbey E; Mydlarz W; Joshi A; London NR; Pierce M; Taylor R; Hong S; Nguyen A; Soon-Shiong P; Schlom J; Gulley JL; Allen CT
J Clin Invest; 2022 Sep; 132(18):. PubMed ID: 35727629
[TBL] [Abstract][Full Text] [Related]
10. Dual inhibition of TGF-β and PD-L1: a novel approach to cancer treatment.
Gulley JL; Schlom J; Barcellos-Hoff MH; Wang XJ; Seoane J; Audhuy F; Lan Y; Dussault I; Moustakas A
Mol Oncol; 2022 Jun; 16(11):2117-2134. PubMed ID: 34854206
[TBL] [Abstract][Full Text] [Related]
11. Dual targeting of TGF-β and PD-L1 via a bifunctional anti-PD-L1/TGF-βRII agent: status of preclinical and clinical advances.
Lind H; Gameiro SR; Jochems C; Donahue RN; Strauss J; Gulley JL; Palena C; Schlom J
J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32079617
[TBL] [Abstract][Full Text] [Related]
12. Programmed Death-1/Programmed Death-Ligand 1-Axis Blockade in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Stratified by Human Papillomavirus Status: A Systematic Review and Meta-Analysis.
Xu Y; Zhu G; Maroun CA; Wu IXY; Huang D; Seiwert TY; Liu Y; Mandal R; Zhang X
Front Immunol; 2021; 12():645170. PubMed ID: 33897693
[TBL] [Abstract][Full Text] [Related]
13. Restricted Recruitment of NK Cells with Impaired Function Is Caused by HPV-Driven Immunosuppressive Microenvironment of Papillomas in Aggressive Juvenile-Onset Recurrent Respiratory Papillomatosis Patients.
Wang W; Xi Y; Li S; Liu X; Wang G; Wang H; Pei M; Zhang J; Gui J; Ni X
J Virol; 2022 Oct; 96(19):e0094622. PubMed ID: 36154611
[TBL] [Abstract][Full Text] [Related]
14. Combined Inhibition of TGF-β Signaling and the PD-L1 Immune Checkpoint Is Differentially Effective in Tumor Models.
Sow HS; Ren J; Camps M; Ossendorp F; Ten Dijke P
Cells; 2019 Apr; 8(4):. PubMed ID: 30959852
[TBL] [Abstract][Full Text] [Related]
15. The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-β and PD-L1.
Yi M; Zhang J; Li A; Niu M; Yan Y; Jiao Y; Luo S; Zhou P; Wu K
J Hematol Oncol; 2021 Feb; 14(1):27. PubMed ID: 33593403
[TBL] [Abstract][Full Text] [Related]
16. Colocalized targeting of TGF-β and PD-L1 by bintrafusp alfa elicits distinct antitumor responses.
Lan Y; Yeung TL; Huang H; Wegener AA; Saha S; Toister-Achituv M; Jenkins MH; Chiu LY; Lazorchak A; Tarcic O; Wang H; Qi J; Locke G; Kalimi D; Qin G; Marelli B; Yu H; Gross AW; Derner MG; Soloviev M; Botte M; Sircar A; Ma H; Sood VD; Zhang D; Jiang F; Lo KM
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35858707
[TBL] [Abstract][Full Text] [Related]
17. Radiolabelling and preclinical characterization of
Burvenich IJG; Goh YW; Guo N; Gan HK; Rigopoulos A; Cao D; Liu Z; Ackermann U; Wichmann CW; McDonald AF; Huynh N; O'Keefe GJ; Gong SJ; Scott FE; Li L; Geng W; Zutshi A; Lan Y; Scott AM
Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3075-3088. PubMed ID: 33608805
[TBL] [Abstract][Full Text] [Related]
18. Clinical Activity of Nivolumab for Human Papilloma Virus-Related Juvenile-Onset Recurrent Respiratory Papillomatosis.
Creelan BC; Ahmad MU; Kaszuba FJ; Khalil FK; Welsh AW; Ozdemirli M; Grant NN; Subramaniam DS
Oncologist; 2019 Jun; 24(6):829-835. PubMed ID: 30842242
[TBL] [Abstract][Full Text] [Related]
19. Immune correlates of clinical parameters in patients with HPV-associated malignancies treated with bintrafusp alfa.
Tsai YT; Strauss J; Toney NJ; Jochems C; Venzon DJ; Gulley JL; Schlom J; Donahue RN
J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35418484
[TBL] [Abstract][Full Text] [Related]
20. Outcomes of bevacizumab and cidofovir treatment in HPV-associated recurrent respiratory papillomatosis - review of the literature.
Jackowska J; Piersiala K; Klimza H; Wierzbicka M
Otolaryngol Pol; 2018 Jun; 72(4):1-8. PubMed ID: 30190442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]